PharmaDiagnostics, a developer of label-free screening technology that does not require specialised instrumentation, has appointed Dr Sylviane Boucharens as director of assay development. She joins from Merck’s MSD site in Newhouse, Scotland, where she was head of global compound repository and in vitro screening.
Boucharens will play a central role in driving the growth of PharmaDiagnostics’ assay product range, and in developing business globally. She worked at Merck from 2000 to 2011. She started her career in the pharmaceutical industry in 1995 when she joined the Immunology Department in the Laboratoires Fournier (Dijon, France).
PharmaDiagnostics appoints director of assay development
Former pharma department head joins Belgian firm
You may also like
Manufacturing
![Alcami invests in quality, packaging and storage upgrades at Tennessee site post-Tjoapack acquisition]()
Alcami invests in quality, packaging and storage upgrades at Tennessee site post-Tjoapack acquisition
The CDMO is integrating the facility into its MasterControl QMS network, adding serialisation-ready packaging lines and expanded GMP temperature-controlled storage, with a new high-speed bottle line live in H1 2027
Design & Build
![Single Use Support launches RoSS.BLST blast freezer with -80 °C recipe-driven protocols]()
Single Use Support launches RoSS.BLST blast freezer with -80 °C recipe-driven protocols
The 21 CFR Part 11 compliant platform offers 30% more chamber capacity within the same footprint, supporting up to 192 × 2L bottles per batch for consistent, scalable biologics freeze-thaw processes
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Neuland Laboratories announces new $20m process development lab in Hyderabad]()
Neuland Laboratories announces new $20m process development lab in Hyderabad
The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs
